UnitedHealth's Senior Unsecured Notes Rated by A.M Best

Various market performance charts

UnitedHealth Group, Inc. 's UNH senior unsecured notes recently received rating action from A.M Best. The rating giant assigned Long-Term Issue Credit Ratings of "bbb+" to the $625 million 3.375% senior unsecured notes, due 2027 and the $725 million 4.25% senior unsecured notes, due 2047. A.M Best has maintained a stable outlook on these credit ratings.

UnitedHealth's focus on effective debt management is evidenced by its healthy balance sheet. The company's strong underwriting results as well as solid fundamentals have cemented shareholder confidence on the stock. In the last one year, the stock has gained 34% while the Zacks categorized Health Maintenance Organization (HMO) industry registered a 23% increase.

The rating agency expects UnitedHealth to repay the outstanding commercial paper borrowings and debt maturities in June and July, utilizing the proceeds from the latest offering. Moreover, the company is expected to reduce financial leverage below 40% by year-end 2017. The company is also likely to reduce share repurchases to balance the equity end of its capital structure. For the remainder of 2017, the company is anticipated to have nearly $2.73 billion of senior unsecured debt.

UnitedHealth's financial flexibility is backed by its commercial paper program, parent company cash, subsidiary dividends and credit facility. In addition, its non-regulated operating earnings and cash flows have given it a competitive advantage. The company's consistently strong earnings as well as solid contribution from Optum operations are also encouraging.

UnitedHealth's financial leverage is likely to remain unchanged following the notes issuance. At the end of 2016, the company's debt-to-capital ratio was 46%, higher than 2015, primarily due to expenses related to the Catamaran Corporation acquisition. Nonetheless, the company maintains a strong interest coverage of 12 times.

Zacks Rank and Stocks to Consider

UnitedHealth presently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from medical sector include HCA Holdings, Inc. HCA , Inogen Inc. INGN and Avinger, Inc. AVGR . While Inogen sports Zacks Rank #1 (Strong Buy), the other two stocks hold a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

HCA Holdings delivered positive surprises in all of the last four quarters with an average beat of 10.16%.

Inogen delivered positive surprises in three of the last four quarters but with an average negative surprise of 49.08%.

Avinger delivered positive surprises in two of the last four quarters with an average beat of 4.35%.

More Stock News: 8 Companies Verge on Apple-Like Run

Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.

A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Inogen, Inc (INGN): Free Stock Analysis Report

UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report

Avinger, Inc. (AVGR): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More